<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00345579</url>
  </required_header>
  <id_info>
    <org_study_id>105987</org_study_id>
    <nct_id>NCT00345579</nct_id>
  </id_info>
  <brief_title>Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 2, 4, 6 and 12 to 15 Months of Age</brief_title>
  <official_title>A Single-blind, Randomized, Controlled, Multinational Study for the Evaluation of Safety of GlaxoSmithKline (GSK) Biologicals' Investigational Vaccination Regimen Compared to Monovalent Haemophilus Influenzae Type b (Hib) Control Vaccine in Healthy Infants at 2, 4, 6, and 12 to 15 Months of Age.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The primary phase of this study is evaluating the safety of Hib-MenCY-TT vaccine compared to
      a control group receiving licensed Hib conjugate vaccine, when each are co-administered with
      Pediarix® to healthy infants at 2, 4, and 6 months of age.

      This protocol posting deals with objectives &amp; outcome measures of the primary phase of the
      study. The objectives &amp; outcome measures of the Booster phase are presented in a separate
      protocol posting (NCT number = 00345683).

      The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pediarix/Infanrix Penta and Prevnar should be co-administered to all subjects in all study
      groups according to a 2, 4, and 6 month schedule concomitantly with study vaccines.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects Reporting Serious Adverse Events (SAEs)</measure>
    <time_frame>From Dose 1 up to Day 30 after Dose 3 (from study Month 0 up to study Month 5)</time_frame>
    <description>SAEs assessed include medical occurrences that results in death, are life threatening, require hospitalization or prolongation of hospitalization, results in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subjects.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Reporting New Onset of Chronic Illnesses (NOCIs)</measure>
    <time_frame>From Dose 1 up to Day 30 after Dose 3 (from study Month 0 up to study Month 5)</time_frame>
    <description>NOCIs include autoimmune disorders, asthma, type I diabetes, allergies.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Reporting Rash</measure>
    <time_frame>From Dose 1 up to Day 30 after Dose 3 (from study Month 0 up to study Month 5)</time_frame>
    <description>Rash assessed was hives, idiopathic thrombocytopenic purpura, petechiae.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Reporting Adverse Events Resulting in Emergency Room (ER)</measure>
    <time_frame>From Dose 1 up to Day 30 after Dose 3 (from study Month 0 up to study Month 5)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Serious Adverse Events (SAEs)</measure>
    <time_frame>From Dose 1 through but excluding the fourth dose (from study Month 0 up to the booster vaccination at 12-15 months of age)</time_frame>
    <description>SAEs assessed include medical occurrences that results in death, are life threatening, require hospitalization or prolongation of hospitalization, results in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subjects.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With New Onset of Chronic Illnesses (NOCIs)</measure>
    <time_frame>From Dose 1 through but excluding the fourth dose (from study Month 0 up to the booster vaccination at 12-15 months of age)</time_frame>
    <description>NOCIs include autoimmune disorders, asthma, type I diabetes, allergies.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Rash</measure>
    <time_frame>From Dose 1 through but excluding the fourth dose (from study Month 0 up to the booster vaccination at 12-15 months of age)</time_frame>
    <description>Rash assessed was hives, idiopathic thrombocytopenic purpura, petechiae</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Adverse Events Resulting in Emergency Room (ER)</measure>
    <time_frame>From Dose 1 through but excluding the fourth dose (from study Month 0 up to the booster vaccination at 12-15 months of age)</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">4432</enrollment>
  <condition>Haemophilus Influenzae Type b</condition>
  <condition>Neisseria Meningitidis</condition>
  <arm_group>
    <arm_group_label>Menhibrix Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received 3 doses of Menhibrix vaccine (at 2, 4 and 6 months of age, study Months 0, 2 and 4), co-administered with Pediarix/Infanrix penta as a primary vaccination course and a fourth dose of Menhibrix vaccine at 12-15 months of age in the study NCT00345683. Menhibrix was administered intramuscularly in the upper right thigh and co-administered Pediarix/Infanrix penta vaccine was injected intramuscularly in the upper left thigh.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ActHIB Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects received 3 doses of ActHIB vaccine (at 2, 4 and 6 months of age, study Months 0, 2 and 4), co-administered with Pediarix/Infanrix penta as a primary vaccination course and 1 dose of PedvaxHib vaccine as a booster at 12-15 months of age in the study NCT00345683. ActHIB and PedvaxHib vaccines were administered intramuscularly in the upper right thigh and co-administered Pediarix/Infanrix penta vaccine was injected intramuscularly in the upper left thigh.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined 792014</intervention_name>
    <description>3-dose intramuscular injection</description>
    <arm_group_label>Menhibrix Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ActHIB</intervention_name>
    <description>3-dose intramuscular injection</description>
    <arm_group_label>ActHIB Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pediarix/Infanrix Penta</intervention_name>
    <description>3-dose intramuscular injection</description>
    <arm_group_label>ActHIB Group</arm_group_label>
    <arm_group_label>Menhibrix Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects for whom the investigator believes that parents/guardians can and will comply
             with the requirements of the protocol.

          -  A male or female between, and including, 6 and 12 weeks of age at the time of the
             first vaccination.

          -  Written informed consent obtained from the parent or guardian of the subject.

          -  Healthy subjects as established by medical history and clinical examination before
             entering into the study.

          -  Born after 36 weeks gestation.

          -  Infants who have not received a previous dose of hepatitis B vaccine or those who have
             received only 1 dose of hepatitis B vaccine administered at least 30 days prior to
             enrolment.

          -  Infants may have received a birth dose of Bacillus Calmette-Guérin (BCG) vaccine.

        Exclusion criteria:

        Use of any investigational or non-registered product (drug or vaccine) other than the study
        vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during
        the study period.

          -  Chronic administration (defined as more than 14 days) of immunosuppressants or other
             immune-modifying drugs since birth.

          -  Planned administration/ administration of a vaccine not foreseen by the study protocol
             within 30 days of the first dose of study vaccine(s).

          -  Previous vaccination against Neisseria meningitidis, Haemophilus influenzae type b,
             diphtheria, tetanus, pertussis, and/or poliovirus; more than one previous dose of
             hepatitis B vaccine.

          -  In country(ies) where Prevnar will be provided by GSK Biologicals, previous
             vaccination with Prevnar.

          -  History of Neisseria meningitidis, Haemophilus influenzae type b, diphtheria, tetanus,
             pertussis, hepatitis B, and/or poliovirus disease.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition based on
             medical history and physical examination.

          -  History of allergic disease or reactions likely to be exacerbated by any component of
             the vaccines, including dry natural latex rubber.

          -  Major congenital defects or serious chronic illness.

          -  History of any neurologic disorders or seizures.

          -  Acute disease at time of enrollment.

          -  Administration of immunoglobulins and/or any blood products since birth or planned
             administration during the study period.

          -  Concurrent participation in another clinical study, at any time during the study
             period, in which the subject has been or will be exposed to an investigational or a
             non-investigational product (pharmaceutical product or device).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Weeks</minimum_age>
    <maximum_age>12 Weeks</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35244</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Benton</city>
        <state>Arkansas</state>
        <zip>72015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fayetteville</city>
        <state>Arkansas</state>
        <zip>72703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <zip>71913</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <zip>72401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93726</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madera</city>
        <state>California</state>
        <zip>93637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Slinas</city>
        <state>California</state>
        <zip>93901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>West Covina</city>
        <state>California</state>
        <zip>91790</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <zip>80303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Longmont</city>
        <state>Colorado</state>
        <zip>80501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nampa</city>
        <state>Idaho</state>
        <zip>208 463 3126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oaklawn</city>
        <state>Illinois</state>
        <zip>60453</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Waukee</city>
        <state>Iowa</state>
        <zip>50263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>West Desmoines</city>
        <state>Iowa</state>
        <zip>50266</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bardstown</city>
        <state>Kentucky</state>
        <zip>40004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bossier City</city>
        <state>Louisiana</state>
        <zip>71111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jamaica Plain</city>
        <state>Massachusetts</state>
        <zip>02130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nies</city>
        <state>Michigan</state>
        <zip>49120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Portage</city>
        <state>Michigan</state>
        <zip>49024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Stevensville</city>
        <state>Michigan</state>
        <zip>49127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>St. Paul</city>
        <state>Minnesota</state>
        <zip>55108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New Hartford</city>
        <state>New York</state>
        <zip>13413</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Clyde</city>
        <state>North Carolina</state>
        <zip>28721</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Deerfield</city>
        <state>North Carolina</state>
        <zip>28607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sylva</city>
        <state>North Carolina</state>
        <zip>28779</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44308-1062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>North Canton</city>
        <state>Ohio</state>
        <zip>44720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>South Euclid</city>
        <state>Ohio</state>
        <zip>44121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wexford</city>
        <state>Pennsylvania</state>
        <zip>15090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37664</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77084</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Katy</city>
        <state>Texas</state>
        <zip>77450</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Layton</city>
        <state>Utah</state>
        <zip>84041</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ogden</city>
        <state>Utah</state>
        <zip>84405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Orem</city>
        <state>Utah</state>
        <zip>84057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pleasant Gorve</city>
        <state>Utah</state>
        <zip>84062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>South Jordan</city>
        <state>Utah</state>
        <zip>84095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <zip>84088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Marshfield</city>
        <state>Wisconsin</state>
        <zip>54449</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mexico city</city>
        <zip>04530</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mexico, D.F.</city>
        <zip>06720</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <reference>
    <citation>Bryant KA, Marshall GS. Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y tetanus toxoid conjugate vaccine for infants and toddlers. Expert Rev Vaccines. 2011 Jul;10(7):941-50. doi: 10.1586/erv.11.90. Review.</citation>
    <PMID>21806393</PMID>
  </reference>
  <reference>
    <citation>Rinderknecht S, Bryant K, Nolan T, Pavia-Ruz N, Doniz CA, Weber MA, Cohen C, Aris E, Mesaros N, Miller JM. The safety profile of Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y tetanus toxoid conjugate vaccine (HibMenCY). Hum Vaccin Immunother. 2012 Mar;8(3):304-11. doi: 10.4161/hv.18752. Epub 2012 Feb 13.</citation>
    <PMID>22327493</PMID>
  </reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 26, 2006</study_first_submitted>
  <study_first_submitted_qc>June 26, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2006</study_first_posted>
  <results_first_submitted>June 15, 2012</results_first_submitted>
  <results_first_submitted_qc>April 20, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 11, 2009</results_first_posted>
  <disposition_first_submitted>April 27, 2009</disposition_first_submitted>
  <disposition_first_submitted_qc>September 25, 2009</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 28, 2009</disposition_first_posted>
  <last_update_submitted>November 3, 2016</last_update_submitted>
  <last_update_submitted_qc>November 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prophylaxis</keyword>
  <keyword>Neisseria meningitidis Vaccines, conjugate</keyword>
  <keyword>Infants</keyword>
  <keyword>Meningococcal vaccines</keyword>
  <keyword>H. influenzae type B vaccine</keyword>
  <keyword>Humans</keyword>
  <keyword>Safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>PENTA</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>105987</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>105987</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>105987</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>105987</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>105987</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>105987</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This summary presents results for the primary vaccination phase up to the end of the extended safety follow-up (until, but excluding, the booster dose at 12-15 months of age). For results about the booster/fourth dose phase, see study NCT00345683.</recruitment_details>
      <pre_assignment_details>Of the 4432 subjects enrolled, 4391 were vaccinated and 4162 completed the primary vaccination phase of the study (3114 in the MenHibrix Group and 1048 in the ActHIB Group).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>MenHibrix Group</title>
          <description>Subjects received 3 doses of MenHibrix vaccine (at 2, 4 and 6 months of age, study Months 0, 2 and 4), co-administered with Pediarix/Infanrix penta as a primary vaccination course and a fourth dose of MenHibrix vaccine at 12-15 months of age in the study NCT00345683. MenHibrix was administered intramuscularly in the upper right thigh and co-administered Pediarix/Infanrix penta vaccine was injected intramuscularly in the upper left thigh.</description>
        </group>
        <group group_id="P2">
          <title>ActHIB Group</title>
          <description>Subjects received 3 doses of ActHIB vaccine (at 2, 4 and 6 months of age, study Months 0, 2 and 4), co-administered with Pediarix/Infanrix penta as a primary vaccination course and 1 dose of PedvaxHib vaccine as a booster at 12-15 months of age in the study NCT00345683. ActHIB and PedvaxHib vaccines were administered intramuscularly in the upper right thigh and co-administered Pediarix/Infanrix penta vaccine was injected intramuscularly in the upper left thigh.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3278"/>
                <participants group_id="P2" count="1113"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3114"/>
                <participants group_id="P2" count="1048"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="164"/>
                <participants group_id="P2" count="65"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MenHibrix Group</title>
          <description>Subjects received 3 doses of MenHibrix vaccine (at 2, 4 and 6 months of age, study Months 0, 2 and 4), co-administered with Pediarix/Infanrix penta as a primary vaccination course and a fourth dose of MenHibrix vaccine at 12-15 months of age in the study NCT00345683. MenHibrix was administered intramuscularly in the upper right thigh and co-administered Pediarix/Infanrix penta vaccine was injected intramuscularly in the upper left thigh.</description>
        </group>
        <group group_id="B2">
          <title>ActHIB Group</title>
          <description>Subjects received 3 doses of ActHIB vaccine (at 2, 4 and 6 months of age, study Months 0, 2 and 4), co-administered with Pediarix/Infanrix penta as a primary vaccination course and 1 dose of PedvaxHib vaccine as a booster at 12-15 months of age in the study NCT00345683. ActHIB and PedvaxHib vaccines were administered intramuscularly in the upper right thigh and co-administered Pediarix/Infanrix penta vaccine was injected intramuscularly in the upper left thigh.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3278"/>
            <count group_id="B2" value="1113"/>
            <count group_id="B3" value="4391"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.6" spread="10.45"/>
                    <measurement group_id="B2" value="59.0" spread="10.39"/>
                    <measurement group_id="B3" value="58.8" spread="10.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1576"/>
                    <measurement group_id="B2" value="557"/>
                    <measurement group_id="B3" value="2133"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1702"/>
                    <measurement group_id="B2" value="556"/>
                    <measurement group_id="B3" value="2258"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Reporting Serious Adverse Events (SAEs)</title>
        <description>SAEs assessed include medical occurrences that results in death, are life threatening, require hospitalization or prolongation of hospitalization, results in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subjects.</description>
        <time_frame>From Dose 1 up to Day 30 after Dose 3 (from study Month 0 up to study Month 5)</time_frame>
        <population>The Primary Total Vaccinated cohort included all subjects with at least one primary vaccine dose of study vaccine administered.</population>
        <group_list>
          <group group_id="O1">
            <title>MenHibrix Group</title>
            <description>Subjects received 3 doses of MenHibrix vaccine (at 2, 4 and 6 months of age, study Months 0, 2 and 4), co-administered with Pediarix/Infanrix penta as a primary vaccination course and a fourth dose of MenHibrix vaccine at 12-15 months of age in the study NCT00345683. MenHibrix was administered intramuscularly in the upper right thigh and co-administered Pediarix/Infanrix penta vaccine was injected intramuscularly in the upper left thigh.</description>
          </group>
          <group group_id="O2">
            <title>ActHIB Group</title>
            <description>Subjects received 3 doses of ActHIB vaccine (at 2, 4 and 6 months of age, study Months 0, 2 and 4), co-administered with Pediarix/Infanrix penta as a primary vaccination course and 1 dose of PedvaxHib vaccine as a booster at 12-15 months of age in the study NCT00345683. ActHIB and PedvaxHib vaccines were administered intramuscularly in the upper right thigh and co-administered Pediarix/Infanrix penta vaccine was injected intramuscularly in the upper left thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Serious Adverse Events (SAEs)</title>
          <description>SAEs assessed include medical occurrences that results in death, are life threatening, require hospitalization or prolongation of hospitalization, results in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subjects.</description>
          <population>The Primary Total Vaccinated cohort included all subjects with at least one primary vaccine dose of study vaccine administered.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3278"/>
                <count group_id="O2" value="1113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Reporting New Onset of Chronic Illnesses (NOCIs)</title>
        <description>NOCIs include autoimmune disorders, asthma, type I diabetes, allergies.</description>
        <time_frame>From Dose 1 up to Day 30 after Dose 3 (from study Month 0 up to study Month 5)</time_frame>
        <population>The Primary Total Vaccinated cohort included all subjects with at least one primary vaccine dose of study vaccine administered.</population>
        <group_list>
          <group group_id="O1">
            <title>MenHibrix Group</title>
            <description>Subjects received 3 doses of MenHibrix vaccine (at 2, 4 and 6 months of age, study Months 0, 2 and 4), co-administered with Pediarix/Infanrix penta as a primary vaccination course and a fourth dose of MenHibrix vaccine at 12-15 months of age in the study NCT00345683. MenHibrix was administered intramuscularly in the upper right thigh and co-administered Pediarix/Infanrix penta vaccine was injected intramuscularly in the upper left thigh.</description>
          </group>
          <group group_id="O2">
            <title>ActHIB Group</title>
            <description>Subjects received 3 doses of ActHIB vaccine (at 2, 4 and 6 months of age, study Months 0, 2 and 4), co-administered with Pediarix/Infanrix penta as a primary vaccination course and 1 dose of PedvaxHib vaccine as a booster at 12-15 months of age in the study NCT00345683. ActHIB and PedvaxHib vaccines were administered intramuscularly in the upper right thigh and co-administered Pediarix/Infanrix penta vaccine was injected intramuscularly in the upper left thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting New Onset of Chronic Illnesses (NOCIs)</title>
          <description>NOCIs include autoimmune disorders, asthma, type I diabetes, allergies.</description>
          <population>The Primary Total Vaccinated cohort included all subjects with at least one primary vaccine dose of study vaccine administered.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3278"/>
                <count group_id="O2" value="1113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Reporting Rash</title>
        <description>Rash assessed was hives, idiopathic thrombocytopenic purpura, petechiae.</description>
        <time_frame>From Dose 1 up to Day 30 after Dose 3 (from study Month 0 up to study Month 5)</time_frame>
        <population>The Primary Total Vaccinated cohort included all subjects with at least one primary vaccine dose of study vaccine administered.</population>
        <group_list>
          <group group_id="O1">
            <title>MenHibrix Group</title>
            <description>Subjects received 3 doses of MenHibrix vaccine (at 2, 4 and 6 months of age, study Months 0, 2 and 4), co-administered with Pediarix/Infanrix penta as a primary vaccination course and a fourth dose of MenHibrix vaccine at 12-15 months of age in the study NCT00345683. MenHibrix was administered intramuscularly in the upper right thigh and co-administered Pediarix/Infanrix penta vaccine was injected intramuscularly in the upper left thigh.</description>
          </group>
          <group group_id="O2">
            <title>ActHIB Group</title>
            <description>Subjects received 3 doses of ActHIB vaccine (at 2, 4 and 6 months of age, study Months 0, 2 and 4), co-administered with Pediarix/Infanrix penta as a primary vaccination course and 1 dose of PedvaxHib vaccine as a booster at 12-15 months of age in the study NCT00345683. ActHIB and PedvaxHib vaccines were administered intramuscularly in the upper right thigh and co-administered Pediarix/Infanrix penta vaccine was injected intramuscularly in the upper left thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Rash</title>
          <description>Rash assessed was hives, idiopathic thrombocytopenic purpura, petechiae.</description>
          <population>The Primary Total Vaccinated cohort included all subjects with at least one primary vaccine dose of study vaccine administered.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3278"/>
                <count group_id="O2" value="1113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="243"/>
                    <measurement group_id="O2" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Reporting Adverse Events Resulting in Emergency Room (ER)</title>
        <time_frame>From Dose 1 up to Day 30 after Dose 3 (from study Month 0 up to study Month 5)</time_frame>
        <population>The Primary Total Vaccinated cohort included all subjects with at least one primary vaccine dose of study vaccine administered.</population>
        <group_list>
          <group group_id="O1">
            <title>MenHibrix Group</title>
            <description>Subjects received 3 doses of MenHibrix vaccine (at 2, 4 and 6 months of age, study Months 0, 2 and 4), co-administered with Pediarix/Infanrix penta as a primary vaccination course and a fourth dose of MenHibrix vaccine at 12-15 months of age in the study NCT00345683. MenHibrix was administered intramuscularly in the upper right thigh and co-administered Pediarix/Infanrix penta vaccine was injected intramuscularly in the upper left thigh.</description>
          </group>
          <group group_id="O2">
            <title>ActHIB Group</title>
            <description>Subjects received 3 doses of ActHIB vaccine (at 2, 4 and 6 months of age, study Months 0, 2 and 4), co-administered with Pediarix/Infanrix penta as a primary vaccination course and 1 dose of PedvaxHib vaccine as a booster at 12-15 months of age in the study NCT00345683. ActHIB and PedvaxHib vaccines were administered intramuscularly in the upper right thigh and co-administered Pediarix/Infanrix penta vaccine was injected intramuscularly in the upper left thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Adverse Events Resulting in Emergency Room (ER)</title>
          <population>The Primary Total Vaccinated cohort included all subjects with at least one primary vaccine dose of study vaccine administered.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3278"/>
                <count group_id="O2" value="1113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Serious Adverse Events (SAEs)</title>
        <description>SAEs assessed include medical occurrences that results in death, are life threatening, require hospitalization or prolongation of hospitalization, results in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subjects.</description>
        <time_frame>From Dose 1 through but excluding the fourth dose (from study Month 0 up to the booster vaccination at 12-15 months of age)</time_frame>
        <population>The Primary Total Vaccinated cohort included all subjects with at least one primary vaccine dose of study vaccine administered.</population>
        <group_list>
          <group group_id="O1">
            <title>MenHibrix Group</title>
            <description>Subjects received 3 doses of MenHibrix vaccine (at 2, 4 and 6 months of age, study Months 0, 2 and 4), co-administered with Pediarix/Infanrix penta as a primary vaccination course and a fourth dose of MenHibrix vaccine at 12-15 months of age in the study NCT00345683. MenHibrix was administered intramuscularly in the upper right thigh and co-administered Pediarix/Infanrix penta vaccine was injected intramuscularly in the upper left thigh.</description>
          </group>
          <group group_id="O2">
            <title>ActHIB Group</title>
            <description>Subjects received 3 doses of ActHIB vaccine (at 2, 4 and 6 months of age, study Months 0, 2 and 4), co-administered with Pediarix/Infanrix penta as a primary vaccination course and 1 dose of PedvaxHib vaccine as a booster at 12-15 months of age in the study NCT00345683. ActHIB and PedvaxHib vaccines were administered intramuscularly in the upper right thigh and co-administered Pediarix/Infanrix penta vaccine was injected intramuscularly in the upper left thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Serious Adverse Events (SAEs)</title>
          <description>SAEs assessed include medical occurrences that results in death, are life threatening, require hospitalization or prolongation of hospitalization, results in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subjects.</description>
          <population>The Primary Total Vaccinated cohort included all subjects with at least one primary vaccine dose of study vaccine administered.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3278"/>
                <count group_id="O2" value="1113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With New Onset of Chronic Illnesses (NOCIs)</title>
        <description>NOCIs include autoimmune disorders, asthma, type I diabetes, allergies.</description>
        <time_frame>From Dose 1 through but excluding the fourth dose (from study Month 0 up to the booster vaccination at 12-15 months of age)</time_frame>
        <population>The Primary Total Vaccinated cohort included all subjects with at least one primary vaccine dose of study vaccine administered.</population>
        <group_list>
          <group group_id="O1">
            <title>MenHibrix Group</title>
            <description>Subjects received 3 doses of MenHibrix vaccine (at 2, 4 and 6 months of age, study Months 0, 2 and 4), co-administered with Pediarix/Infanrix penta as a primary vaccination course and a fourth dose of MenHibrix vaccine at 12-15 months of age in the study NCT00345683. MenHibrix was administered intramuscularly in the upper right thigh and co-administered Pediarix/Infanrix penta vaccine was injected intramuscularly in the upper left thigh.</description>
          </group>
          <group group_id="O2">
            <title>ActHIB Group</title>
            <description>Subjects received 3 doses of ActHIB vaccine (at 2, 4 and 6 months of age, study Months 0, 2 and 4), co-administered with Pediarix/Infanrix penta as a primary vaccination course and 1 dose of PedvaxHib vaccine as a booster at 12-15 months of age in the study NCT00345683. ActHIB and PedvaxHib vaccines were administered intramuscularly in the upper right thigh and co-administered Pediarix/Infanrix penta vaccine was injected intramuscularly in the upper left thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With New Onset of Chronic Illnesses (NOCIs)</title>
          <description>NOCIs include autoimmune disorders, asthma, type I diabetes, allergies.</description>
          <population>The Primary Total Vaccinated cohort included all subjects with at least one primary vaccine dose of study vaccine administered.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3278"/>
                <count group_id="O2" value="1113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Rash</title>
        <description>Rash assessed was hives, idiopathic thrombocytopenic purpura, petechiae</description>
        <time_frame>From Dose 1 through but excluding the fourth dose (from study Month 0 up to the booster vaccination at 12-15 months of age)</time_frame>
        <population>The Primary Total Vaccinated cohort included all subjects with at least one primary vaccine dose of study vaccine administered.</population>
        <group_list>
          <group group_id="O1">
            <title>MenHibrix Group</title>
            <description>Subjects received 3 doses of MenHibrix vaccine (at 2, 4 and 6 months of age, study Months 0, 2 and 4), co-administered with Pediarix/Infanrix penta as a primary vaccination course and a fourth dose of MenHibrix vaccine at 12-15 months of age in the study NCT00345683. MenHibrix was administered intramuscularly in the upper right thigh and co-administered Pediarix/Infanrix penta vaccine was injected intramuscularly in the upper left thigh.</description>
          </group>
          <group group_id="O2">
            <title>ActHIB Group</title>
            <description>Subjects received 3 doses of ActHIB vaccine (at 2, 4 and 6 months of age, study Months 0, 2 and 4), co-administered with Pediarix/Infanrix penta as a primary vaccination course and 1 dose of PedvaxHib vaccine as a booster at 12-15 months of age in the study NCT00345683. ActHIB and PedvaxHib vaccines were administered intramuscularly in the upper right thigh and co-administered Pediarix/Infanrix penta vaccine was injected intramuscularly in the upper left thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Rash</title>
          <description>Rash assessed was hives, idiopathic thrombocytopenic purpura, petechiae</description>
          <population>The Primary Total Vaccinated cohort included all subjects with at least one primary vaccine dose of study vaccine administered.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3278"/>
                <count group_id="O2" value="1113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="386"/>
                    <measurement group_id="O2" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Adverse Events Resulting in Emergency Room (ER)</title>
        <time_frame>From Dose 1 through but excluding the fourth dose (from study Month 0 up to the booster vaccination at 12-15 months of age)</time_frame>
        <population>The Primary Total Vaccinated cohort included all subjects with at least one primary vaccine dose of study vaccine administered.</population>
        <group_list>
          <group group_id="O1">
            <title>MenHibrix Group</title>
            <description>Subjects received 3 doses of MenHibrix vaccine (at 2, 4 and 6 months of age, study Months 0, 2 and 4), co-administered with Pediarix/Infanrix penta as a primary vaccination course and a fourth dose of MenHibrix vaccine at 12-15 months of age in the study NCT00345683. MenHhibrix was administered intramuscularly in the upper right thigh and co-administered Pediarix/Infanrix penta vaccine was injected intramuscularly in the upper left thigh.</description>
          </group>
          <group group_id="O2">
            <title>ActHIB Group</title>
            <description>Subjects received 3 doses of ActHIB vaccine (at 2, 4 and 6 months of age, study Months 0, 2 and 4), co-administered with Pediarix/Infanrix penta as a primary vaccination course and 1 dose of PedvaxHib vaccine as a booster at 12-15 months of age in the study NCT00345683. ActHIB and PedvaxHib vaccines were administered intramuscularly in the upper right thigh and co-administered Pediarix/Infanrix penta vaccine was injected intramuscularly in the upper left thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Adverse Events Resulting in Emergency Room (ER)</title>
          <population>The Primary Total Vaccinated cohort included all subjects with at least one primary vaccine dose of study vaccine administered.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3278"/>
                <count group_id="O2" value="1113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="198"/>
                    <measurement group_id="O2" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious Adverse Events: From Dose 1 through but excluding the fourth dose (from study Month 0 up to the booster vaccination at 12-15 months of age)</time_frame>
      <desc>Solicited symptoms and unsolicited AEs were not collected during the study. Only information about specific categories of AEs (SAEs, NOCIs, rash and AEs resulting in ER visits) were collected in this study.</desc>
      <group_list>
        <group group_id="E1">
          <title>MenHibrix Group</title>
          <description>Subjects received 3 doses of MenHibrix vaccine (at 2, 4 and 6 months of age, study Months 0, 2 and 4), co-administered with Pediarix/Infanrix penta as a primary vaccination course and a fourth dose of MenHibrix vaccine at 12-15 months of age in the study NCT00345683. MenHibrix was administered intramuscularly in the upper right thigh and co-administered Pediarix/Infanrix penta vaccine was injected intramuscularly in the upper left thigh.</description>
        </group>
        <group group_id="E2">
          <title>ActHIB Group</title>
          <description>Subjects received 3 doses of ActHIB vaccine (at 2, 4 and 6 months of age, study Months 0, 2 and 4), co-administered with Pediarix/Infanrix penta as a primary vaccination course and 1 dose of PedvaxHib vaccine as a booster at 12-15 months of age in the study NCT00345683. ActHIB and PedvaxHib vaccines were administered intramuscularly in the upper right thigh and co-administered Pediarix/Infanrix penta vaccine was injected intramuscularly in the upper left thigh.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="157" subjects_at_risk="3278"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="1113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <description>From Dose 1 through but excluding the fourth dose (from study Month 0 up to the booster vaccination at 12-15 months of age)</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <description>From Dose 1 through but excluding the fourth dose (from study Month 0 up to the booster vaccination at 12-15 months of age)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3278"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Ileus</sub_title>
                <description>From Dose 1 through but excluding the fourth dose (from study Month 0 up to the booster vaccination at 12-15 months of age)</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1113"/>
              </event>
              <event>
                <sub_title>Inguinal hernia, obstructive</sub_title>
                <description>From Dose 1 through but excluding the fourth dose (from study Month 0 up to the booster vaccination at 12-15 months of age)</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1113"/>
              </event>
              <event>
                <sub_title>Intussusception</sub_title>
                <description>From Dose 1 through but excluding the fourth dose (from study Month 0 up to the booster vaccination at 12-15 months of age)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3278"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1113"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>From Dose 1 through but excluding the fourth dose (from study Month 0 up to the booster vaccination at 12-15 months of age)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3278"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1113"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <description>From Dose 1 through but excluding the fourth dose (from study Month 0 up to the booster vaccination at 12-15 months of age)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3278"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1113"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <description>From Dose 1 through but excluding the fourth dose (from study Month 0 up to the booster vaccination at 12-15 months of age)</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1113"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <description>From Dose 1 through but excluding the fourth dose (from study Month 0 up to the booster vaccination at 12-15 months of age)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3278"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <description>From Dose 1 through but excluding the fourth dose (from study Month 0 up to the booster vaccination at 12-15 months of age)</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1113"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <description>From Dose 1 through but excluding the fourth dose (from study Month 0 up to the booster vaccination at 12-15 months of age)</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3278"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1113"/>
              </event>
              <event>
                <sub_title>Sudden infant death syndrome</sub_title>
                <description>From Dose 1 through but excluding the fourth dose (from study Month 0 up to the booster vaccination at 12-15 months of age)</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3278"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <description>From Dose 1 through but excluding the fourth dose (from study Month 0 up to the booster vaccination at 12-15 months of age)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3278"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Perirectal abscess</sub_title>
                <description>From Dose 1 through but excluding the fourth dose (from study Month 0 up to the booster vaccination at 12-15 months of age)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3278"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1113"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <description>From Dose 1 through but excluding the fourth dose (from study Month 0 up to the booster vaccination at 12-15 months of age)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3278"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1113"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <description>From Dose 1 through but excluding the fourth dose (from study Month 0 up to the booster vaccination at 12-15 months of age)</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1113"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <description>From Dose 1 through but excluding the fourth dose (from study Month 0 up to the booster vaccination at 12-15 months of age)</description>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="3278"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="1113"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <description>From Dose 1 through but excluding the fourth dose (from study Month 0 up to the booster vaccination at 12-15 months of age)</description>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="3278"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1113"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <description>From Dose 1 through but excluding the fourth dose (from study Month 0 up to the booster vaccination at 12-15 months of age)</description>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="3278"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="1113"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <description>From Dose 1 through but excluding the fourth dose (from study Month 0 up to the booster vaccination at 12-15 months of age)</description>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="3278"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1113"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus bronchiolitis</sub_title>
                <description>From Dose 1 through but excluding the fourth dose (from study Month 0 up to the booster vaccination at 12-15 months of age)</description>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="3278"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1113"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <description>From Dose 1 through but excluding the fourth dose (from study Month 0 up to the booster vaccination at 12-15 months of age)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3278"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1113"/>
              </event>
              <event>
                <sub_title>Gastroenteritis rotavirus</sub_title>
                <description>From Dose 1 through but excluding the fourth dose (from study Month 0 up to the booster vaccination at 12-15 months of age)</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3278"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1113"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <description>From Dose 1 through but excluding the fourth dose (from study Month 0 up to the booster vaccination at 12-15 months of age)</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1113"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <description>From Dose 1 through but excluding the fourth dose (from study Month 0 up to the booster vaccination at 12-15 months of age)</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1113"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus infection</sub_title>
                <description>From Dose 1 through but excluding the fourth dose (from study Month 0 up to the booster vaccination at 12-15 months of age)</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1113"/>
              </event>
              <event>
                <sub_title>Croup infectious</sub_title>
                <description>From Dose 1 through but excluding the fourth dose (from study Month 0 up to the booster vaccination at 12-15 months of age)</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1113"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <description>From Dose 1 through but excluding the fourth dose (from study Month 0 up to the booster vaccination at 12-15 months of age)</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3278"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1113"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <description>From Dose 1 through but excluding the fourth dose (from study Month 0 up to the booster vaccination at 12-15 months of age)</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1113"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <description>From Dose 1 through but excluding the fourth dose (from study Month 0 up to the booster vaccination at 12-15 months of age)</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1113"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <description>From Dose 1 through but excluding the fourth dose (from study Month 0 up to the booster vaccination at 12-15 months of age)</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3278"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1113"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <description>From Dose 1 through but excluding the fourth dose (from study Month 0 up to the booster vaccination at 12-15 months of age)</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3278"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1113"/>
              </event>
              <event>
                <sub_title>Tracheitis</sub_title>
                <description>From Dose 1 through but excluding the fourth dose (from study Month 0 up to the booster vaccination at 12-15 months of age)</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3278"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1113"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <description>From Dose 1 through but excluding the fourth dose (from study Month 0 up to the booster vaccination at 12-15 months of age)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3278"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1113"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <description>From Dose 1 through but excluding the fourth dose (from study Month 0 up to the booster vaccination at 12-15 months of age)</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1113"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <description>From Dose 1 through but excluding the fourth dose (from study Month 0 up to the booster vaccination at 12-15 months of age)</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1113"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <description>From Dose 1 through but excluding the fourth dose (from study Month 0 up to the booster vaccination at 12-15 months of age)</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1113"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <description>From Dose 1 through but excluding the fourth dose (from study Month 0 up to the booster vaccination at 12-15 months of age)</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1113"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <description>From Dose 1 through but excluding the fourth dose (from study Month 0 up to the booster vaccination at 12-15 months of age)</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1113"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <description>From Dose 1 through but excluding the fourth dose (from study Month 0 up to the booster vaccination at 12-15 months of age)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3278"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fractured skull depressed</sub_title>
                <description>From Dose 1 through but excluding the fourth dose (from study Month 0 up to the booster vaccination at 12-15 months of age)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3278"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1113"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <description>From Dose 1 through but excluding the fourth dose (from study Month 0 up to the booster vaccination at 12-15 months of age)</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1113"/>
              </event>
              <event>
                <sub_title>Skull fractured base</sub_title>
                <description>From Dose 1 through but excluding the fourth dose (from study Month 0 up to the booster vaccination at 12-15 months of age)</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1113"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <description>From Dose 1 through but excluding the fourth dose (from study Month 0 up to the booster vaccination at 12-15 months of age)</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1113"/>
              </event>
              <event>
                <sub_title>Subdural haemorrhage</sub_title>
                <description>From Dose 1 through but excluding the fourth dose (from study Month 0 up to the booster vaccination at 12-15 months of age)</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1113"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <description>From Dose 1 through but excluding the fourth dose (from study Month 0 up to the booster vaccination at 12-15 months of age)</description>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="3278"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1113"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <description>From Dose 1 through but excluding the fourth dose (from study Month 0 up to the booster vaccination at 12-15 months of age)</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1113"/>
              </event>
              <event>
                <sub_title>Anastomotic leak</sub_title>
                <description>From Dose 1 through but excluding the fourth dose (from study Month 0 up to the booster vaccination at 12-15 months of age)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3278"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1113"/>
              </event>
              <event>
                <sub_title>Burns second degree</sub_title>
                <description>From Dose 1 through but excluding the fourth dose (from study Month 0 up to the booster vaccination at 12-15 months of age)</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1113"/>
              </event>
              <event>
                <sub_title>Eye injury</sub_title>
                <description>From Dose 1 through but excluding the fourth dose (from study Month 0 up to the booster vaccination at 12-15 months of age)</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1113"/>
              </event>
              <event>
                <sub_title>Skin injury</sub_title>
                <description>From Dose 1 through but excluding the fourth dose (from study Month 0 up to the booster vaccination at 12-15 months of age)</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <description>From Dose 1 through but excluding the fourth dose (from study Month 0 up to the booster vaccination at 12-15 months of age)</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3278"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1113"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <description>From Dose 1 through but excluding the fourth dose (from study Month 0 up to the booster vaccination at 12-15 months of age)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3278"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1113"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <description>From Dose 1 through but excluding the fourth dose (from study Month 0 up to the booster vaccination at 12-15 months of age)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3278"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <description>From Dose 1 through but excluding the fourth dose (from study Month 0 up to the booster vaccination at 12-15 months of age)</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3278"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1113"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <description>From Dose 1 through but excluding the fourth dose (from study Month 0 up to the booster vaccination at 12-15 months of age)</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1113"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <description>From Dose 1 through but excluding the fourth dose (from study Month 0 up to the booster vaccination at 12-15 months of age)</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1113"/>
              </event>
              <event>
                <sub_title>Nystagmus</sub_title>
                <description>From Dose 1 through but excluding the fourth dose (from study Month 0 up to the booster vaccination at 12-15 months of age)</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3278"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1113"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <description>From Dose 1 through but excluding the fourth dose (from study Month 0 up to the booster vaccination at 12-15 months of age)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3278"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1113"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <description>From Dose 1 through but excluding the fourth dose (from study Month 0 up to the booster vaccination at 12-15 months of age)</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Breath holding</sub_title>
                <description>From Dose 1 through but excluding the fourth dose (from study Month 0 up to the booster vaccination at 12-15 months of age)</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <description>From Dose 1 through but excluding the fourth dose (from study Month 0 up to the booster vaccination at 12-15 months of age)</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <description>From Dose 1 through but excluding the fourth dose (from study Month 0 up to the booster vaccination at 12-15 months of age)</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Lung disorder</sub_title>
                <description>From Dose 1 through but excluding the fourth dose (from study Month 0 up to the booster vaccination at 12-15 months of age)</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1113"/>
              </event>
              <event>
                <sub_title>Bronchial hyperreactivity</sub_title>
                <description>From Dose 1 through but excluding the fourth dose (from study Month 0 up to the booster vaccination at 12-15 months of age)</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3278"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1113"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <description>From Dose 1 through but excluding the fourth dose (from study Month 0 up to the booster vaccination at 12-15 months of age)</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1113"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <description>From Dose 1 through but excluding the fourth dose (from study Month 0 up to the booster vaccination at 12-15 months of age)</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1113"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <description>From Dose 1 through but excluding the fourth dose (from study Month 0 up to the booster vaccination at 12-15 months of age)</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3278"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Child abuse</sub_title>
                <description>From Dose 1 through but excluding the fourth dose (from study Month 0 up to the booster vaccination at 12-15 months of age)</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <description>From Dose 1 through but excluding the fourth dose (from study Month 0 up to the booster vaccination at 12-15 months of age)</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1113"/>
              </event>
              <event>
                <sub_title>Haemorrhagic infarction</sub_title>
                <description>From Dose 1 through but excluding the fourth dose (from study Month 0 up to the booster vaccination at 12-15 months of age)</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1113"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <description>From Dose 1 through but excluding the fourth dose (from study Month 0 up to the booster vaccination at 12-15 months of age)</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1113"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Solicited symptoms and unslocited AEs were not collected during this study. Only information about specific categories of AEs (SAEs, NOCIs, rash and AEs resulting in ER visits) were collected in this study.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

